MAFBaricitinib Tablet 2 mg, 4 mg
Treatment of adult patients with rheumatoid arthritis
Additional Clinical Criteria
Adult patients with rheumatoid arthritis (Initial)
The patient on initial application:
• has at least moderate disease activity as measured by a DAS28 score >= 3.2 and >= 6 swollen and/or tender joints; and
• has failed >=2 combinations of non-biologic DMARDs at optimal doses for >= 3 months unless contraindicated by documented significant toxicity;
The above criteria is valid for 6 months. To continue treatment, please reapply under 'Renewal'.
Adult patients with rheumatoid arthritis (Renewal)
The patient on subsequent reapplication:
• demonstrates at least a moderate EULAR response from baseline:
• Present DAS28 <= 3.2 and good response (DAS28 improvement > 1.2); or
• Present DAS28 <= 3.2 and moderate response (DAS28 improvement > 0.6 and ≤ 1.2); or
• Present DAS28 > 3.2 to <= 5.1 and moderate response (DAS28 improvement > 0.6); or
• Present DAS28 > 5.1 and moderate response (DAS28 improvement >1.2).
Reassessment should be conducted every 6 months and treatment continued only if there is clear evidence of ongoing clinical benefit.